Put Your AAV On The Fast-Track To The Clinic
Source: Catalent

In this whitepaper, Catalent Cell & Gene Therapy experts George Buchman, Ph.D., Research Fellow, and Bhargavi Kondragunta, Ph.D., Director, Internal R&D and Product Development, explain Catalent’s approach to fast-tracking AAVs through a platform approach that is consistent and scalable, along with providing clients with Catalent’s clonal cell-line and off-the-shelf plasmids for a one-stop integrated solution. The authors provide a blueprint for a complete platform approach, enabling a process that easily scales as the project progresses to late-stage GMP production and to market.
access the White Paper!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
Catalent
This website uses cookies to ensure you get the best experience on our website. Learn more